세계의 헤르페스 감염 치료 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2023-2030년)

Herpes infection refers to the infection caused by the herpes simplex virus (HSV). The symptoms of herpes infection include core sores and fever blister. It can be diagnosed with the help of physical treatment, fluid sampling as well as blood tests etc. Currently, herpes infection is not curable, but there are some medications that help reduce the symptoms, relieve pain and prevent the transmission of the virus. The medications include famciclovir, acyclovir and valacyclovir. 

Market Dynamics:

The main factor responsible for the demand for herpes infection treatment market is the increasing prevalence of diseases such as diabetes and hypertension.The rise in the low immunity aliment population and a growing number of people suffering chronic diseases are contributing to the demand for this market. An increase in hospital-acquired infections coupled with a lack of sanitary practices in developing countries is surging the demand for this market. Major players in the market are focusing on the expansion of product portfolios and meeting the high demand for improvised treatment options. Growing research and development activities, along with increasing emphasis on developing antiviral medications for orolabial and genital herpes, are expanding the demand for this market. Growing investment in the healthcare sector and the launch of new products is augmenting the demand for this market.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of herpes infection treatment. The growth and trends of herpes infection treatment industry provide a holistic approach to this study. 

Market Segmentation:

This section of the herpes infection treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities. 

By Product

• Therapeutics
• Vaccine

By Type

• Herpes Simplex (Herpes Simplex 1, Herpes Simplex 2)
• Herpes Zoster

By Drug

• Acyclovir
• Valacyclovir
• Famciclovir
• Others

By Route Of Administration

• Oral
• Topical
• Injection

By Herpes Vaccine

• Herpes Simplex
• Herpes Zoster

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Regional Analysis

This section covers the regional outlook, which accentuates current and future demand for the Herpes Infection Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the herpes infection treatment market include Teva Pharmaceutical Industries Ltd., Abbott, GlaxoSmithKline plc, Cipla Inc., Eli Lilly and Company, Merck & Co. Inc., Novartis AG, F. Hoffmann-La Roche Ltd. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

TABLE OF CONTENTS

1 . PREFACE

• 1.1. Report Description
  • 1.1.1. Objective
  • 1.1.2. Target Audience
  • 1.1.3. Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1. Market Research Process
  • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3 . HERPES INFECTION TREATMENT - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Product
  • 3.7.2 Market Attractiveness Analysis By Type
  • 3.7.3 Market Attractiveness Analysis By Drug
  • 3.7.4 Market Attractiveness Analysis By Route Of Administration
  • 3.7.5 Market Attractiveness Analysis By Herpes Vaccine
  • 3.7.6 Market Attractiveness Analysis By Distribution Channel
  • 3.7.7 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1. List of Raw Materials
  • 4.2.2. Raw Material Manufactures List
  • 4.2.3. Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1. Direct Marketing
  • 4.4.2. Indirect Marketing
  • 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL HERPES INFECTION TREATMENT MARKET ANALYSIS BY PRODUCT

• 6.1 Overview by Product
• 6.2 Historical and Forecast Data
• 6.3 Analysis by Product
• 6.4 Therapeutics Historic and Forecast Sales by Regions
• 6.5 Vaccine Historic and Forecast Sales by Regions

7 . GLOBAL HERPES INFECTION TREATMENT MARKET ANALYSIS BY TYPE

• 7.1 Overview by Type
• 7.2 Historical and Forecast Data
• 7.3 Analysis by Type
• 7.4 Herpes Simplex (Herpes Simplex 1, Herpes Simplex 2) Historic and Forecast Sales by Regions
• 7.5 Herpes Zoster Historic and Forecast Sales by Regions

8 . GLOBAL HERPES INFECTION TREATMENT MARKET ANALYSIS BY DRUG

• 8.1 Overview by Drug
• 8.2 Historical and Forecast Data
• 8.3 Analysis by Drug
• 8.4 Acyclovir Historic and Forecast Sales by Regions
• 8.5 Valacyclovir Historic and Forecast Sales by Regions
• 8.6 Famciclovir Historic and Forecast Sales by Regions
• 8.7 Others Historic and Forecast Sales by Regions

9 . GLOBAL HERPES INFECTION TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

• 9.1 Overview by Route Of Administration
• 9.2 Historical and Forecast Data
• 9.3 Analysis by Route Of Administration
• 9.4 Oral Historic and Forecast Sales by Regions
• 9.5 Topical Historic and Forecast Sales by Regions
• 9.6 Injection Historic and Forecast Sales by Regions

10 . GLOBAL HERPES INFECTION TREATMENT MARKET ANALYSIS BY HERPES VACCINE

• 10.1 Overview by Herpes Vaccine
• 10.2 Historical and Forecast Data
• 10.3 Analysis by Herpes Vaccine
• 10.4 Herpes Simplex Historic and Forecast Sales by Regions
• 10.5 Herpes Zoster Historic and Forecast Sales by Regions

11 . GLOBAL HERPES INFECTION TREATMENT MARKET ANALYSIS BY DISTRIBUTION CHANNEL

• 11.1 Overview by Distribution Channel
• 11.2 Historical and Forecast Data
• 11.3 Analysis by Distribution Channel
• 11.4 Hospital Pharmacy Historic and Forecast Sales by Regions
• 11.5 Retail Pharmacy Historic and Forecast Sales by Regions
• 11.6 Online Pharmacy Historic and Forecast Sales by Regions

12 . GLOBAL HERPES INFECTION TREATMENT MARKET SALES ANALYSIS BY GEOGRAPHY

• 12.1. Regional Outlook
• 12.2. Introduction
• 12.3. North America Sales Analysis
  • 12.3.1. Overview, Historic and Forecast Sales Analysis
  • 12.3.2. North America By Segment Sales Analysis
  • 12.3.3. North America By Country Sales Analysis
  • 12.3.4. United State Sales Analysis
  • 12.3.5. Canada Sales Analysis
  • 12.3.6. Mexico Sales Analysis
• 12.4. Europe Sales Analysis
  • 12.4.1. Overview, Historic and Forecast Sales Analysis
  • 12.4.2. Europe by Segment Sales Analysis
  • 12.4.3. Europe by Country Sales Analysis
  • 12.4.4. United Kingdom Sales Analysis
  • 12.4.5. France Sales Analysis
  • 12.4.6. Germany Sales Analysis
  • 12.4.7. Italy Sales Analysis
  • 12.4.8. Russia Sales Analysis
  • 12.4.9. Rest Of Europe Sales Analysis
• 12.5. Asia Pacific Sales Analysis
  • 12.5.1. Overview, Historic and Forecast Sales Analysis
  • 12.5.2. Asia Pacific by Segment Sales Analysis
  • 12.5.3. Asia Pacific by Country Sales Analysis
  • 12.5.4. China Sales Analysis
  • 12.5.5. India Sales Analysis
  • 12.5.6. Japan Sales Analysis
  • 12.5.7. South Korea Sales Analysis
  • 12.5.8. Australia Sales Analysis
  • 12.5.9. Rest Of Asia Pacific Sales Analysis
• 12.6. Latin America Sales Analysis
  • 12.6.1. Overview, Historic and Forecast Sales Analysis
  • 12.6.2. Latin America by Segment Sales Analysis
  • 12.6.3. Latin America by Country Sales Analysis
  • 12.6.4. Brazil Sales Analysis
  • 12.6.5. Argentina Sales Analysis
  • 12.6.6. Peru Sales Analysis
  • 12.6.7. Chile Sales Analysis
  • 12.6.8. Rest of Latin America Sales Analysis
• 12.7. Middle East & Africa Sales Analysis
  • 12.7.1. Overview, Historic and Forecast Sales Analysis
  • 12.7.2. Middle East & Africa by Segment Sales Analysis
  • 12.7.3. Middle East & Africa by Country Sales Analysis
  • 12.7.4. Saudi Arabia Sales Analysis
  • 12.7.5. UAE Sales Analysis
  • 12.7.6. Israel Sales Analysis
  • 12.7.7. South Africa Sales Analysis
  • 12.7.8. Rest Of Middle East And Africa Sales Analysis

13 . COMPETITIVE LANDSCAPE OF THE HERPES INFECTION TREATMENT COMPANIES

• 13.1. Herpes Infection Treatment Market Competition
• 13.2. Partnership/Collaboration/Agreement
• 13.3. Merger And Acquisitions
• 13.4. New Product Launch
• 13.5. Other Developments

14 . COMPANY PROFILES OF HERPES INFECTION TREATMENT INDUSTRY

• 14.1. Top  Company Share Analysis
• 14.2. Market Concentration Rate
• 14.3. Teva Pharmaceutical Industries Ltd.
  • 14.3.1. Company Overview
  • 14.3.2. Company Revenue
  • 14.3.3. Products
  • 14.3.4. Recent Developments
• 14.4. Abbott
  • 14.4.1. Company Overview
  • 14.4.2. Company Revenue
  • 14.4.3. Products
  • 14.4.4. Recent Developments
• 14.5. GlaxoSmithKline plc
  • 14.5.1. Company Overview
  • 14.5.2. Company Revenue
  • 14.5.3. Products
  • 14.5.4. Recent Developments
• 14.6. Cipla Inc.
  • 14.6.1. Company Overview
  • 14.6.2. Company Revenue
  • 14.6.3. Products
  • 14.6.4. Recent Developments
• 14.7. Eli Lilly and Company
  • 14.7.1. Company Overview
  • 14.7.2. Company Revenue
  • 14.7.3. Products
  • 14.7.4. Recent Developments
• 14.8. Merck & Co. Inc.
  • 14.8.1. Company Overview
  • 14.8.2. Company Revenue
  • 14.8.3. Products
  • 14.8.4. Recent Developments
• 14.9. Novartis AG
  • 14.9.1. Company Overview
  • 14.9.2. Company Revenue
  • 14.9.3. Products
  • 14.9.4. Recent Developments
• 14.10. F. Hoffmann-La Roche Ltd.
  • 14.10.1. Company Overview
  • 14.10.2. Company Revenue
  • 14.10.3. Products
  • 14.10.4. Recent Developments

 *Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies